GreenLight Biosciences (GRNA)

Company Profile

GreenLight Biosciences Holdings, PBC is a pre-commercial stage biotechnology company with a proprietary cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. Our vision is to pave the way for a sustainable planet through widely available and affordable RNA products. We are developing RNA products for plant and life science applications to advance crop management, plant protection, animal health, vaccine development and pandemic preparation. We have a pipeline of product candidates across various stages of development.

Company profile

Ticker

GRNA

Exchange

Incorporated

Location

Fiscal year end

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Exelixis ...

Former names

Environmental Impact Acquisition Corp

SEC CIK

0001822691

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

GreenLight Biosciences Holdings • GreenLight Security Corporation • GreenLight Biosciences Espana, S.L. ...

IRS number

851914700

GRNA stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

8-K

Cost Associated with Exit or Disposal Activities

31 May 23

SC14D9C

Written communication relating to third party tender offer

30 May 23

8-K

GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by

11 May 23

GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

11 May 23

EFFECT

Notice of effectiveness

31 Mar 23

8-K

GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line

30 Mar 23

POS AM

Prospectus update (post-effective amendment)

GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results

28 Mar 23

Latest ownership filings

View all

Initial statement of insider ownership

Morningside Venture Investments Ltd

7 Jun 23

SC 13D

Jeremy & Hannelore Grantham Environmental Trust

7 Jun 23

Initial statement of insider ownership

Series Greenlight, a separate series of BlueIO Growth LLC

7 Jun 23

Caitlin Macadino

7 Jun 23

Ifeyinwa Jane Iwuchukwu

7 Jun 23

Lorenzo Aulisa

7 Jun 23

Financial summary

Financial statements Chart GRNA financial data

Quarter (USD)	Mar 23	Dec 22	Sep 22	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	33.76 mm	33.76 mm	33.76 mm	33.76 mm	33.76 mm	33.76 mm
Cash burn (monthly)	11.89 mm	4.23 mm	9.43 mm	13.02 mm	10.35 mm	9.86 mm
Cash used (since last report)	27.08 mm	9.64 mm	21.49 mm	29.67 mm	23.59 mm	22.46 mm
Cash remaining	6.68 mm	24.12 mm	12.27 mm	4.09 mm	10.17 mm	11.30 mm
Runway (months of cash)	0.6	5.7	1.3	0.3	1.0	1.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2023

GRNA institutional ownership history Ownership history

51.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	63	64	-1.6%
Opened positions	10	12	-16.7%
Closed positions	11	6	+83.3%
Increased positions	17	29	-41.4%
Reduced positions	17	8	+112.5%

13F shares	Current	Prev Q	Change
Total value	9.91 bn	24.82 bn	-60.1%
Total shares	77.55 mm	71.90 mm	+7.9%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Morningside Venture Investments	13.86 mm	$0.00	0.0%
Kodiak Venture Partners Iii	9.81 mm	$0.00	0.0%
Cormorant Asset Management	9.19 mm	$3.97 mm	0.0%
Fall Line Endurance Fund	8.90 mm	$4.13 mm	NEW
Fall Line Endurance GP	8.90 mm	$0.00	0.0%
Continental Grain	6.49 mm	$2.80 bn	0.0%
BLK Blackrock	4.96 mm	$2.14 bn	-6.5%
Tao Capital Management	2.67 mm	$1.16 mm	0.0%
Hudson Bay Capital Management	1.77 mm	$765.39 mm	-9.8%
Board of Trustees of The Leland Stanford Junior University	1.69 mm	$728.95 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Fall Line Endurance Fund	8.90 mm	+8.90 mm	NEW
Highbridge Capital Management	0.00	-1.69 mm	EXIT
Baird Financial	965.08 k	-588.39 k	-37.9%
BLK Blackrock	4.96 mm	-344.11 k	-6.5%
Renaissance Technologies	256.30 k	+256.30 k	NEW
BNP Paribas Asset Management Holding	704.92 k	-250.55 k	-26.2%
Regents Of The University Of California	0.00	-198.31 k	EXIT
STT State Street	1.00 mm	-196.24 k	-16.4%
Hudson Bay Capital Management	1.77 mm	-191.77 k	-9.8%
Swiss National Bank	0.00	-182.93 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.